IMMUNOBRAIN

ImmunoBrain is a clinical-stage biopharmaceutical company committed to developing innovative immunotherapies for neurological disorders... At ImmunoBrain, we are pioneering a paradigm shift, building on the groundbreaking discovery that the peripheral immune system, particularly monocytes and T-cells, plays a crucial role in maintaining brain health and function. We propose that activating the peripheral immune system, specifically through modulating immune checkpoint pathways (e.g. the PD-1/PD-L1 pathway), can provide a novel and effective means of combating neurodegenerative disorders, enhancing the immune system's ability to clear pathogenic factors in the brain. This innovative approach potentially opens new avenues for the treatment of neurodegeneration... Our therapeutic approach, rooted in over two decades of studies out of the lab of Professor Michal Schwartz at the Weizmann Institute of Science, has shown that transient intermittent blockade of the PD-1/PD-L1 pathway..

Also known as: Immunobrain Checkpoint Inc., Immunobrain Inc.

Primary location: London United Kingdom